SCHEMBL18282170

SCHEMBL18282170

COC(=O)c1c(Br)c(C)nn1-c1nc(-c2ccccc2)c(SC(C)C)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.36
HPGD P15428 2/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
PTGER1 P34995 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
MAPT P10636 2/20 0.35
ALOX5 P09917 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282066 0.92 MYC (0.38) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL18282243 0.91 MAPK14 (0.36) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL18282195 0.90 ALDH1A1 (0.39) MEN1KMT2AALDH1A1KDM4ESLC22A12
SCHEMBL18282078 0.90 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL18282209 0.90 MYC (0.39) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL18282277 0.90 FNTA (0.42) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL18282126 0.89 SLC6A3 (0.36) KMT2AKDM4ELMNAL3MBTL1MAPT
SCHEMBL18282144 0.89 PIK3CD (0.35) ALDH1A1KDM4ENPC1RAB9A
SCHEMBL18282149 0.88 ALDH1A1 (0.34) MEN1KMT2AALDH1A1KDM4EPOLB
SCHEMBL18282293 0.87 MYC (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases BANTAM PHARMACEUTICAL, LLC (US) 2024-11-26 US disclosed
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto BANTAM PHARMACEUTICAL, LLC (US) 2023-03-14 US disclosed
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto BANTAM PHARMACEUTICAL, LLC 2020-08-20 US disclosed
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases BANTAM PHARMACEUTICAL, LLC 2020-03-05 US disclosed
CN-110769823-A Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases 班塔姆制药有限责任公司 2020-02-07 CN disclosed
EP-3548024-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bantam Pharmaceutical, LLC (US) 2019-10-09 EP disclosed
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EGENIX, INC. 2018-11-01 US disclosed
WO-2018102452-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BANTAM PHARMACEUTICAL, LLC (US) 2018-06-07 WO disclosed
EP-3303332-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO Bantam Pharmaceutical, LLC (US) 2018-04-11 EP disclosed
WO-2016196644-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO BANTAM PHARMACEUTICAL, LLC (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A1, EIF4A3, EIF4B MEN1 2499/4885KMT2A 971/4885ALDH1A1 3399/4885
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A3, EIF4A1, EIF4B MEN1 2981/4885KMT2A 812/4885ALDH1A1 2335/4885
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases KRAS, TP53, CCNA1 MEN1 1870/4885KMT2A 2222/4885ALDH1A1 480/4885
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases KRAS, TP53, CCNA1 MEN1 1870/4885KMT2A 2222/4885ALDH1A1 480/4885
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto EIF4A1, EIF4A3, EIF4B MEN1 2499/4885KMT2A 971/4885ALDH1A1 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.